Ann: Investor Presentation, page-2

FDA EUA Clearance for SARS-CoV-2 expected this quarter - We knew that from previous announcement.
First mention of "First US Customer" for SARS-CoV-2? - great news as they say it'll be first of many in the US market and most likely to move onto other multiplex kits.

STI-Genital kit is another big step (biggest global addressable market), it'll more than double our revenue once we get the approval.

Combine this with last quarterly update, indicative revenue for April alone is ~1.7M. With new 3 potential customers in Europe (if all successful), the minimum contracted uptake is greater than $3.7M. Conservative estimate if 1/3 of that revenue falls into Q4, it'll be ~$1.2M. Adding revenue from regular customers for May, June on top of that. You know what I mean I'll stop there...

I'll be topping up more as i believe we'll see long term uptrend in SP.